|Awarded On||August 18, 2021|
|Title||Targeting lymphotoxin beta receptor in sensory neurons for control of chemotherapy-induced neuropathic pain|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas Health Science Center at San Antonio|
|Principal Investigator/Program Director||Alexei Tumanov|
|Cancer Sites||All Sites|
*Pending contract negotiation
Chemotherapy-induced peripheral neuropathy (CIPN) is the most unwanted aspect of chemotherapy during cancer treatment. Painful CIPN not only affects patients’ quality of life, but often leads to termination of life saving chemotherapy. Currently there is no therapeutic strategies to prevent painful CIPN development. The conventionally used opioids and antidepressants have limited success. Hence, it is crucial to reveal mechanisms controlling development of painful CIPN. We revealed a novel immune regulator, lymphotoxin beta receptor (LTbR) as critical molecule controlling the development of CIPN pain in mice. Importantly, pharmacological inhibition of LTbR prevented the development of CIPN p...